EGFR and non-small cell lung carcinoma: Turke et al.’s (61) study found that a small number of cells (<1%) with MET gene amplification could be detected in samples from NSCLC patients before using EGFR TKIs, while a large number of cells with MET amplification were present after EGFR TKI resistance, indicating that the small fraction of cells with MET gene amplification before treatment ultimately led to resistance.